ATE293456T1 - Behandlung und bestimmung von gram-positiven kokkeninfektionen - Google Patents

Behandlung und bestimmung von gram-positiven kokkeninfektionen

Info

Publication number
ATE293456T1
ATE293456T1 AT97930642T AT97930642T ATE293456T1 AT E293456 T1 ATE293456 T1 AT E293456T1 AT 97930642 T AT97930642 T AT 97930642T AT 97930642 T AT97930642 T AT 97930642T AT E293456 T1 ATE293456 T1 AT E293456T1
Authority
AT
Austria
Prior art keywords
methods
treatment
same
gram
determination
Prior art date
Application number
AT97930642T
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE293456T1 publication Critical patent/ATE293456T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97930642T 1996-07-06 1997-07-07 Behandlung und bestimmung von gram-positiven kokkeninfektionen ATE293456T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614274.0A GB9614274D0 (en) 1996-07-06 1996-07-06 Treatment and diagnosis of infections of gram positive cocci
PCT/GB1997/001830 WO1998001154A2 (en) 1996-07-06 1997-07-07 Treatment and diagnosis of infections of gram positive cocci

Publications (1)

Publication Number Publication Date
ATE293456T1 true ATE293456T1 (de) 2005-05-15

Family

ID=10796521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930642T ATE293456T1 (de) 1996-07-06 1997-07-07 Behandlung und bestimmung von gram-positiven kokkeninfektionen

Country Status (13)

Country Link
US (2) US6544516B1 (de)
EP (1) EP0917471B1 (de)
JP (1) JP2001505534A (de)
AT (1) ATE293456T1 (de)
AU (1) AU717332B2 (de)
CA (1) CA2259141C (de)
DE (1) DE69733067T2 (de)
DK (1) DK0917471T3 (de)
ES (1) ES2238080T3 (de)
GB (1) GB9614274D0 (de)
NZ (1) NZ332991A (de)
PT (1) PT917471E (de)
WO (1) WO1998001154A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
GB9806762D0 (en) * 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
EP1624064A3 (de) * 1998-07-27 2006-05-10 Microbial Technics Limited Nukleinsäuren und entsprechende Proteine aus streptococcus pneumoniae
EP1397502A2 (de) * 2001-01-17 2004-03-17 Avestha Gengraine Technologies PVT Ltd Dna-sequenzierung des abc-transporters oder mehrfach arzneistoffresistenten proteins für bessere umweltstress tolerierende pflanzenkulturen
EP1443957A4 (de) * 2001-05-08 2005-10-12 Texas A & M Univ Sys Oberflächenproteine aus grampositiven bakterien mit hochkonservierten motiven sowie diese erkennende antikörper
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
EP2450053B1 (de) * 2010-11-05 2016-06-15 Universitätsklinikum Freiburg Neuartiges Antigen von Enterokokkenpathogenen und ihre Verwendung als Impfstoffkomponenten für Therapie und/oder Prophylaxe
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
CA2119013A1 (en) * 1991-09-16 1993-04-01 Richard R. Lesniewski Hepatitis c assay
GB9401689D0 (en) * 1994-01-28 1994-03-23 Univ Manchester Diagnosis and treatment of endocarditis

Also Published As

Publication number Publication date
JP2001505534A (ja) 2001-04-24
EP0917471B1 (de) 2005-04-20
DE69733067T2 (de) 2006-01-26
DE69733067D1 (de) 2005-05-25
GB9614274D0 (en) 1996-09-04
CA2259141C (en) 2007-12-11
US6881410B2 (en) 2005-04-19
AU3452297A (en) 1998-02-02
PT917471E (pt) 2005-07-29
EP0917471A2 (de) 1999-05-26
WO1998001154A2 (en) 1998-01-15
CA2259141A1 (en) 1998-01-15
NZ332991A (en) 1999-06-29
AU717332B2 (en) 2000-03-23
DK0917471T3 (da) 2005-06-06
ES2238080T3 (es) 2005-08-16
US20030119101A1 (en) 2003-06-26
WO1998001154A3 (en) 1998-06-25
US6544516B1 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
TR200200633T2 (tr) Yeni streptococcus antijenleri
ATE461938T1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
MXPA03000103A (es) Antigenos de streptococcus.
EP1194164B8 (de) Prion protein peptide und deren verwendung
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
AP2000001886A0 (en) Group B streptococcus antigens.
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
WO1996040940A3 (en) A human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
ATE293456T1 (de) Behandlung und bestimmung von gram-positiven kokkeninfektionen
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
GB0102145D0 (en) Substances
IL159479A (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
WO2007118077A3 (en) Mycobacterial catalase-peroxidase in the diagnosis and treatment of sarcoidosis
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
FI971879L (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
GB9715177D0 (en) Medicament
EP1950302A3 (de) Streptokokken-Antigene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0917471

Country of ref document: EP

REN Ceased due to non-payment of the annual fee